FFO
VNDA icon

Fortitude Family Office’s Vanda Pharmaceuticals VNDA Stock Holding History

Fortitude Family Office’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$319 Hold
65
– – ﹤0.01% 2465
2026
Q2 		$398 Buy
+65
New +$425 ﹤0.01% 2013

Other funds holding VNDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
CFS
CGC Financial Services Lake Oswego, Oregon $451M AUM 11.72% 1-Year Est. Return
GIA
GHP Investment Advisors Denver, Colorado $2.68B AUM 19.3% 1-Year Est. Return

Fortitude Family Office's VNDA Position: Q3 2026 in Review

Fortitude Family Office held its Vanda Pharmaceuticals (VNDA) position steady in Q3 2026 at 65 shares worth $319. The position accounts for ﹤0.01% of the portfolio, ranked #2465.

Fortitude Family Office first reported a position in VNDA in Q2 2026 and has held it in 2 quarters since. The position peaked at $398 in Q2 2026. 10 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • Fortitude Family Office held 65 shares of Vanda Pharmaceuticals worth $319 as of Q3 2026.
  • Fortitude Family Office left its Vanda Pharmaceuticals share count unchanged in Q3 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2465 holding.
  • Fortitude Family Office first reported a position in Vanda Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Fortitude Family Office's Vanda Pharmaceuticals position peaked at $398 in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.